InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
58,062.50
(
2.49%
)
Post# of 30990
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

haysaw

Send PM Follow Ignore
Followers 14
Posts 2972
Boards Moderated 0
Alias Born 07/19/2006

haysaw

Re: haysaw post# 22645

Saturday, 04/18/2015 11:34:49 AM

Saturday, April 18, 2015 11:34:49 AM

Post# of 30990

He noted that the FDA last August issued a clinical hold order, which directed the company not to proceed with a proposed trial in the U.S. “until safety issues raised by the FDA are resolved,” the filing states.



My final point: What are the "safety issues" he refers to? I thought the NDIN "response" had to due with the declaration of Anatabine citrate as a drug. It doesn't say anywhere in the filings about concerns over safety.

Messages posted by individuals may be misleading, deceptive, or in error. If you disagree with a posting, feel free to voice your opinion. It is the policy of iHub to allow our members to freely discuss issues in a free and open manner

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up